Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

At Week 96 of the Single-Tablet Regimen (STaR) study, more treatment-naïve subjects that received rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) developed resistance mutations compared to those treated with efavirenz (EFV)/FTC/TDF by population sequencing. Furthermore, more RPV/FTC/TDF-treated...

Full description

Bibliographic Details
Main Authors: Danielle P. Porter, Martin Daeumer, Alexander Thielen, Silvia Chang, Ross Martin, Cal Cohen, Michael D. Miller, Kirsten L. White
Format: Article
Language:English
Published: MDPI AG 2015-12-01
Series:Viruses
Subjects:
rilpivirine
efavirenz
resistance
virologic failure
minority variants
Online Access:http://www.mdpi.com/1999-4915/7/12/2943

Similar Items

Similar Items